rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
15
|
pubmed:dateCreated |
2000-9-1
|
pubmed:abstractText |
To determine the effect of polymorphic variations in the tumor necrosis factor alpha (TNFalpha) and lymphotoxin alpha (LTalpha) genes on the predisposition to myeloma and the effect of these polymorphisms on response to treatment and overall survival.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0732-183X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2843-51
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10920132-Adult,
pubmed-meshheading:10920132-Aged,
pubmed-meshheading:10920132-Antineoplastic Agents,
pubmed-meshheading:10920132-Case-Control Studies,
pubmed-meshheading:10920132-Disease Progression,
pubmed-meshheading:10920132-Disease-Free Survival,
pubmed-meshheading:10920132-Female,
pubmed-meshheading:10920132-Genetic Predisposition to Disease,
pubmed-meshheading:10920132-Haplotypes,
pubmed-meshheading:10920132-Humans,
pubmed-meshheading:10920132-Lymphotoxin-alpha,
pubmed-meshheading:10920132-Male,
pubmed-meshheading:10920132-Middle Aged,
pubmed-meshheading:10920132-Multiple Myeloma,
pubmed-meshheading:10920132-Polymorphism, Genetic,
pubmed-meshheading:10920132-Prognosis,
pubmed-meshheading:10920132-Risk Factors,
pubmed-meshheading:10920132-Survival Analysis,
pubmed-meshheading:10920132-Tumor Markers, Biological,
pubmed-meshheading:10920132-Tumor Necrosis Factor-alpha
|
pubmed:year |
2000
|
pubmed:articleTitle |
High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.
|
pubmed:affiliation |
Department of Haematology, Leeds General Infirmary and University of Leeds, UK.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|